Answers are grounded in this paper and cite their sources.
Background: Benign vocal fold lesions are important causes of dysphonia, but nodules, polyps and cysts differ in tissue architecture and remodelling. Histopathology describes these differences, while immunohistochemistry for interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) may provide additional information about inflammation and extracellular-matrix turnover. This study characterises the reported tissue patterns and compares available IL-6/MMP-9 immunoreactivity data for nodules and polyps. Methods: The manuscript synthesises histological descriptions and photomicrographs in the supplied clinical manuscript with the available morphometric and immunohistochemical summary tables. The clinical series included 102 patients: 34 with nodules, 40 with polyps and 28 with cysts. The separate IHC tables reported 22 nodule specimens, 20 polyp specimens and 40 controls. Features included epithelial hyperplasia, basement-membrane changes, fibrosis, hyalinosis, stromal oedema, vascular changes and inflammatory infiltration. IL-6 and MMP-9 were reported as H-scores. Results: Nodules showed epithelial hyperplasia, focal parakeratosis, basement-membrane thickening, lamina-propria fibrosis and chronic lymphoplasmacytic infiltration. Polyps showed stromal oedema, myxoid change, dilated thin-walled vessels and perivascular inflammation. Cysts showed a circumscribed subepithelial cavity with epithelial lining and a fibrous wall. In the IHC summaries, nodules had IL-6 and MMP-9 H-scores of 72.4±15.6 and 58.7±14.2, respectively, compared with 18.5±7.2 and 15.1±6.4 in controls. Polyps had scores of 86.1±18.4 and 76.5±17.8. Source tables mark lesion-versus-control differences as p<0.05, but exact p-values and tests were not supplied. Conclusions: The source material supports distinct morphological patterns across nodules, polyps and cysts. Available IHC summaries indicate higher IL-6 and MMP-9 immunoreactivity in nodules and polyps than in controls. These observations are hypothesis-generating; the discrepancy between clinical and IHC sample sizes, missing assay details and incomplete cyst IHC data must be resolved before submission.
No takes yet. Share an insight, caveat, or question.
Xaydarova. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: